Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Impressive results with cilta-cel CAR-T cell therapy in CARTITUDE 4 trial compared to standard triplets in relapsed myeloma.
We as a myeloma community are now gonna have provide guidelines on Tec-Dara and cilta-cel in early relapse, especially 1st relapse.”
More updates from ASH25 on OncoDaily.